These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 32914720)

  • 1. Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.
    Narayanankutty A
    Recent Pat Anticancer Drug Discov; 2020; 15(3):188-199. PubMed ID: 32914720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy.
    Narayanankutty A
    Curr Top Med Chem; 2021; 21(20):1816-1831. PubMed ID: 34279200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.
    Narayanankutty A
    Curr Drug Targets; 2019; 20(12):1217-1226. PubMed ID: 31215384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.
    Ghayad SE; Cohen PA
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):29-57. PubMed ID: 19751211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
    Gonzalez-Angulo AM; Blumenschein GR
    Cancer Treat Rev; 2013 Jun; 39(4):313-20. PubMed ID: 23218708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
    Burris HA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.
    Grunt TW; Mariani GL
    Curr Cancer Drug Targets; 2013 Feb; 13(2):188-204. PubMed ID: 23215720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts.
    McKenna M; McGarrigle S; Pidgeon GP
    Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):185-197. PubMed ID: 30318472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
    Abraham J
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):51-68. PubMed ID: 25306975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy.
    Tewari D; Patni P; Bishayee A; Sah AN; Bishayee A
    Semin Cancer Biol; 2022 May; 80():1-17. PubMed ID: 31866476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.
    Cidado J; Park BH
    J Mammary Gland Biol Neoplasia; 2012 Dec; 17(3-4):205-16. PubMed ID: 22865098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation.
    Sharma VR; Gupta GK; Sharma AK; Batra N; Sharma DK; Joshi A; Sharma AK
    Curr Pharm Des; 2017; 23(11):1633-1638. PubMed ID: 27848885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
    Brufsky AM
    Breast J; 2014; 20(4):347-57. PubMed ID: 24861776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phytochemicals and Nanoparticles in the Modulation of PI3K/Akt/mTOR Kinases and its Implications in the Development and Progression of Gastrointestinal Cancers: A Review of Preclinical and Clinical Evidence.
    Narayanankutty A; Nambiattil S; Mannarakkal S
    Recent Pat Anticancer Drug Discov; 2023; 18(3):307-324. PubMed ID: 35670354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
    Han Y; Wang J; Wang Z; Xu B
    Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects.
    Miricescu D; Totan A; Stanescu-Spinu II; Badoiu SC; Stefani C; Greabu M
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer.
    Zhu K; Wu Y; He P; Fan Y; Zhong X; Zheng H; Luo T
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.